Clinical signifance of glatiramer acetate antibodies

Multiple Sclerosis

Volumn 13, Issue SUPPL. 1, 2007, Pages

  Blanchette, Francois ^a  

^a Teva Pharma SA   (France)

Author keywords

Antigen or antigen based therapy; Copaxone; GA; Glatimer acetate; Interferon; Neutralizing antibodies; Non neutralizing antibodies; Therapeutic efficacy

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; DRUG ANTIBODY; GAMMA INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; MYELIN BASIC PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT BETA INTERFERON; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DETERIORATION; DISEASE COURSE; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; RECURRENCE RISK; REMYELINIZATION; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 34250664645     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507076994     Document Type: Article

References (79)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-87.
2. Ben-Nun A, Mendel I, Bakimer R, Fridkis-Hareli M, Teitelbaum D et al. The autoimmune reactivity to myelin oligodendrocy-te glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer I on MOG-induced disease. J Neurol 1996; 243(Suppl 1): S14-22.
3. Tejada-Simon MV, Zang YC, Yang D, Hong J, Li S et al. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol 2000; 12: 1641-50.
4. Hellings N, Baree M, Verhoeven C, D'hooghe MB, Medaer R et al. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res 2001; 63: 290-302.
5. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurol 1995; 45: 1268-76.
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
7. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurol 1993; 43: 655-61.
8. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
9. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-53.
10. Coclet-Ninin J, Dayer JM, Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 1997; 8: 345-49.
11. Wang X. Chen M, Wandinger KP, Williams G, Dhib-Jalbut S. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J Immunol 2000; 165: 548-57.
12. Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferon beta-1b. J Clin Invest 1997; 100: 604-12.
13. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF, VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49: 1111-16.
14. Stuve O, Dooley NP, Uhm. JH, Antel JP, Francis GS et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63.
15. Hartung HP, Munschauer F 3rd, Schellekens H. Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol 2005; 12: 588-601.
16. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163: 882-85.
17. Lok AS, W CL, Leung EK. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12: 1266-70.
18. Prummer O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 1993; 71: 1828-34.
19. Dummer R, Muller W, Nestle F et al. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 1991; 67: 2300-304.
20. Fierlbeck G, Schreiner T, Schaber B et al. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunol Immunother 1994; 39: 263-68.
21. Herndon RM, Rudick RA, Munschauer FE 3rd, et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005; 11: 409-19.
22. Francis GS, Rice GP, Alsop JC et al. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
23. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
24. Li DK, Zhao GJ, Paty DW et al. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-13.
25. Polman C, Kappos L, White R et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003; 60: 37-43.
26. Bitsch A, Dressel A, Meier K et al. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. J Neurol 2004; 251: 1498-501.
27. Giovannoni G, Goodman A. Neutralizing anti-IFNß antibodies: How much more evidence do we need to use them in practice? Neurology 2005; 65: 6-8.
28. Francis GS, Rice GP, Alsop JC, PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.
29. Kappos L. Clanet M, Sandberg-Wollheim M et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
30. Sorensen PS, Koch-Henriksen N, Ross C et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
31. Bertolotto A, Malucchi S, Milano E et al. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48: 95-100.
32. Perini P, Facchinetti A, Bulian P et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001; 12: 56-61.
33. Kivisakk P, Alm GV, Fredrikson S, Link H. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 2000; 7: 27-34.
34. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998; 51: 1698-702.
35. Tomassini V, Paolillo A, Russo P et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2005; Sep 14, Epub ahead of print. Accessed 15, September 2005.
36. Teitelbaum D, Aharoni R, Sela M, Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 1991; 88: 9528-32.
37. Aharoni R, Teitelbaum D, Sela M. Arnon R. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1997; 94: 10821-26.
38. Miller A. Shapiro S, Gershtein R et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 and Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113-21.
39. Neuhaus O, Farina C, Yassouridis A et al. Multiple sclerosis: comparison of copolymer-1-reactive T-cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000; 97: 7452-57.
40. Weber MS, Starck M, Wagenpfeil S et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004; 127: 1370-78.
41. Kim HJ, Ifergan I, Antel JP et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144-53.
42. Dhib-Jalbut S, Chen M, Said A et al. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol 2003; 140: 163-71.
43. Arnon R. Sela M. Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit 2003; 16: 412-21.
44. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 2003; 215: 37-44.
45. Ziemssen T, Kumpfel T, Schneider H et al. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. J Neurol Sci 2005; 233: 109-12.
46. Aharoni R, Kayhan B, Eilam R et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003; 100: 14157-62.
47. Hong J, Li N, Zhang X, Zheng B. Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005; 102: 6449-54.
48. Putheti P. Soderstrom M, Link H, Huang YM. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol 2003; 144: 125-31.
49. Karandikar NJ, Crawford MP, Yan X et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 2002; 109: 641-49.
50. Kim HJ, Ifergan I. Antel JP et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144-53.
51. Chabot S, Yong FP, Le DM et al. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler 2002; 8: 299-306.
52. Aharoni R. Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998; 91: 135-46.
53. Aharoni R. Arnon R. Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005; 25: 8217-28.
54. Maier K, Kuhnert AV, Taheir N, Sättler MB et al. Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol 2006; 169: 1353-64.
55. Brenner T, Arnon R, Sela M et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115: 152-60.
56. Farina C, Vargas V. Heydari N et al. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J Neuroimmunol 2002; 123: 188-92.
57. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Ann Rev Immunol 1990; 8: 773-93.
58. Schalke BC, Klinkert WE, Wekerle H, Dwyer DS. Enhanced activation of a T cell line specific for acetylcholine receptor (AChR) by using anti-AChR monoclonal antibodies plus receptors. J Immunol 1985; 134: 3643-48.
59. Aharoni R, Teitelbaum D, Arnon R, Sela M. Copolymer 1 inhibits manifestations of graft rejection. Transplantation 2001; 72: 598-605.
60. Webb C, Teitelbaum D, Arnon R, Sela M. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 1973; 3: 279-86.
61. Teitelbaum D, Abaroni R, Arnon R, Sela M. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop-1. Proc Natl Acad Sci USA 1988; 85: 9724-28.
62. Teitelbaum D, Milo R, Arnon R, Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 1992; 89: 137-41.
63. Teitelbaum D, Brenner T, Abramsky O et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003; 9: 592-99.
64. Basile E, Gibbs E, Aziz T, Oger J. During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol 2006; 177: 161-66.
65. Ishizaka A, Sakiyama Y, Nakanishi M et al. The inductive effect of interleukin-4 on IgG4 and IgE synthesis in human peripheral blood lymphocytes. Clin Exp Immunol 1990; 79: 392-96.
66. Lanzavecchia, A. Receptor-mediated antigen uptake and its effect on antigen presentation to Class II-restricted T lymphocytes. Ann Rev Immunol 1990; 8: 773-93.
67. Schalke BCG, Flinkert WEF, Wekerle H, Dusyer DS. Enhanced activation of a T cell line specific for acetylcholine receptor (AChR) by using anti-AChR monoclonal antibodies plus receptors. J Immunol 1985; 34: 3643-48.
68. Bornstein MR, Miller A, Slagle S, Weitzmann M et al. A pilot trial of Copolymer 1 in exacerbating - remitting multiple sclerosis. N Engl J Med 1987; 317: 408-14.
69. Meiner Z, Kott E, Schechter D et al. Copolymer 1 in relapsing-remitting multiple sclerosis: a multi-centre trial. In Abramsky O, Ovadia H eds. Frontiers in multiple sclerosis: clinical research and therapy. Martin Dunitz, 1997:213-21.
70. Johnson KP, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate, and degree of disability. Neurology 1998; 50: 701-708.
71. Johnson KP, Brooks BR, Ford CC et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000; 6: 255-66.
72. Johnson KP, Ford CC, Lisak RP, Wolinsky JS. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005; 111: 42-47.
73. Sindic CJ, Seeldrayers P, Vande Gaer L et al. Long-term follow up of glatiramer acetate compassionate use in Belgium. Acta Neurol Belg 2005; 105: 81-85.
74. Zhang JY, Luo XG, Xian CJ et al. Endogenous BDNF is required for myelination and regeneration of injured sciatic nerve in rodents. Eur J Neurosci 2000; 12: 4171-80.
75. Li L, Xu Q, Wu Y et al. Combined therapy of methylprednisolone and brain-derived neurotrophic factor promotes axonal regeneration and functional recovery after spinal cord injury in rats. Chin Med J (Engl) 2003; 116: 414-18.
76. Sarchielli P, Greco L, Stipa A et al. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002; 132: 180-88.
77. Ure DR, Rodriguez M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating diseases. FASEB 2002; 16: 1260-62.
78. Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46: 538-45.
79. Salama HH, Hong J, Zang YCQ et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. Brain 2003; 126: 2638-47.